Predictive and Prognostic Biomarker Identification in a Large Cohort of Androgen Receptor-Positive Salivary Duct Carcinoma Patients Scheduled for Combined Androgen Blockade
Authors:
- Gerben LasscheGLGerben Lassche
- Yuichiro TadaYTYuichiro Tada
- Carla M. L. van HerpenCHCarla M. L. van Herpen
- Marianne A. JonkerMJMarianne A. Jonker
- Toshitaka NagaoToshitaka Nagao
- Takashi SaotomeTSTakashi Saotome
- Hideaki HiraiHHHideaki Hirai
- Natsuki SaigusaNSNatsuki Saigusa
- Hideaki TakahashiHTHideaki Takahashi
- Hiroya OjiriHOHiroya Ojiri
- Adriana C. H. van Engen-Van GrunsvenAGAdriana C. H. van Engen-Van Grunsven
- Jack A. SchalkenJack A. Schalken
Open Access
Abstract
Patients suffering from recurrent or metastatic (R/M) salivary duct carcinoma (SDC) are often treated with combined androgen blockade (CAB). However, CAB frequently fails, resulting in a worse prognosis. Therefore, biomarkers that can predict treatment failure are urgently needed. mRNA from 76 R/M androgen receptor (AR)-positive SDC patients treated with leuprorelin acetate combined with bicalutamide was extracted from pre-treatment tumor specimens. AR, Notch, MAPK, TGFβ, estrogen receptor (ER), Hedgehog (HH), and PI3K signaling pathway activity scores (PAS) were determined based on the expression levels of target genes. Additionally, 5-alpha reductase type 1 (SRD5A1) expression was determined. These markers were related to clinical benefit (complete/partial response or stable disease ≥6 months) and progression-free and overall survival (PFS/OS). SRD5A1 expression had the highest general predictive value for clinical benefit and positive predictive value (PPV: 85.7%). AR PAS had the highest negative predictive value (NPV: 93.3%). The fitting of a multivariable model led to the identification of SRD5A1, TGFβ, and Notch PAS as the most predictive combination. High AR, high Notch, high ER, low HH PAS, and high SRD5A1 expression were also of prognostic importance regarding PFS and SRD5A1 expression levels for OS. AR, Notch PAS, and SRD5A1 expression have the potential to predict the clinical benefit of CAB treatment in SDC patients. SRD5A1 expression can identify patients that will and AR PAS patients that will not experience clinical benefit (85.7% and 93.3% for PPV and NPV, respectively). The predictive potential of SRD5A1 expression forms a rational basis for including SRD5A1-inhibitors in SDC patients’ treatment.Keywords
This publication has 40 references indexed in Scilit:
- EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II—2020 Update: Treatment of Relapsing and Metastatic Prostate CancerEuropean Urology, 2021
- Systemic therapy in the management of recurrent or metastatic salivary duct carcinoma: A systematic reviewCancer Treatment Reviews, 2020
- Salivary duct carcinoma: Updates in histology, cytology, molecular biology, and treatmentCancer Cytopathology, 2020
- Advances and challenges in precision medicine in salivary gland cancerCancer Treatment Reviews, 2019
- Phase II Trial of Trastuzumab and Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Salivary Duct CarcinomaJournal of Clinical Oncology, 2019
- A clinicopathological study and prognostic factor analysis of 177 salivary duct carcinoma patients from The NetherlandsInternational Journal of Cancer, 2018
- Androgen deprivation therapy for androgen receptor‐positive advanced salivary duct carcinoma: A nationwide case series of 35 patients in The NetherlandsHead & Neck, 2017
- A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinomaAnnals of Oncology, 2017
- Salivary duct carcinoma: An aggressive salivary gland malignancy with opportunities for targeted therapyOral Oncology, 2017
- Clinical Outcomes and Prognostic Factors for Salivary Duct Carcinoma: A Multi-Institutional Analysis of 141 PatientsAnnals of Surgical Oncology, 2016